BECTON, DICKINSON AND COMPANY (BDX) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.79%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 1.26%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.79% | Research and development expense / revenue. Period ending 2026-06-30. $1.30B ÷ $22.48B × 100 ≈ 5.79% |
| Stock-based compensation / revenue · 12 months | 1.26% | Share-based compensation / revenue. Period ending 2026-06-30. $283.00M ÷ $22.48B × 100 ≈ 1.26% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 1.30B USD | Research and Development Expense |
| Revenue | 22.48B USD | |
| Stock-based compensation | 283.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 2.40B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.30B | $22.48B | $283.00M | $2.40B | (m) | 5.79% | 1.26% | (m) | (m) |
| 2026-03-31 | $1.27B | $22.23B | $276.00M | $2.48B | (m) | 5.73% | 1.24% | (m) | (m) |
| 2025-12-31 | $1.23B | $21.92B | $259.00M | $2.68B | (m) | 5.60% | 1.18% | (m) | (m) |
| 2025-09-30 | $1.26B | $21.84B | $258.00M | $2.58B | $613.00M | 5.79% | 1.18% | 4.21× | Reported |
| 2025-06-30 | $1.25B | $21.39B | $254.00M | $2.50B | (m) | 5.82% | 1.19% | (m) | (m) |
| 2025-03-31 | $1.25B | $20.87B | $253.00M | $2.22B | (m) | 5.98% | 1.21% | (m) | (m) |
| 2024-12-31 | $1.24B | $20.64B | $254.00M | $2.41B | (m) | 6.02% | 1.23% | (m) | (m) |
| 2024-09-30 | $1.19B | $20.18B | $247.00M | $2.40B | $528.00M | 5.90% | 1.22% | 4.54× | Reported |
| 2024-06-30 | $1.17B | $19.83B | $254.00M | $2.12B | (m) | 5.90% | 1.28% | (m) | (m) |
| 2024-03-31 | $1.18B | $19.72B | $257.00M | $2.07B | $468.00M | 5.96% | 1.30% | 4.43× | Reported |
| 2023-12-31 | $1.21B | $19.49B | $253.00M | $1.97B | $461.00M | 6.23% | 1.30% | 4.26× | Reported |
| 2023-09-30 | $1.24B | $19.37B | $259.00M | $2.11B | $452.00M | 6.39% | 1.34% | 4.67× | Reported |
| 2023-06-30 | $1.26B | $19.05B | $250.00M | $2.25B | $443.00M | 6.59% | 1.31% | 5.08× | Reported |
| 2023-03-31 | $1.27B | $18.81B | $244.00M | $2.24B | $423.00M | 6.73% | 1.30% | 5.29× | Reported |
| 2022-12-31 | $1.25B | $18.74B | $241.00M | $2.17B | $402.00M | 6.70% | 1.29% | 5.41× | Reported |
| 2022-09-30 | $1.26B | $18.87B | $233.00M | $2.28B | $398.00M | 6.66% | 1.23% | 5.73× | Reported |
| 2022-06-30 | $1.38B | $20.07B | $239.00M | $2.72B | $405.00M | 6.89% | 1.19% | 6.72× | Reported |
| 2022-03-31 | $1.40B | $20.03B | $239.00M | $2.59B | $426.00M | 7.01% | 1.19% | 6.08× | Reported |
| 2021-12-31 | $1.38B | $19.93B | $237.00M | $2.37B | $449.00M | 6.91% | 1.19% | 5.29× | Reported |
| 2021-09-30 | $1.34B | $20.25B | $237.00M | $2.80B | $469.00M | 6.61% | 1.17% | 5.97× | Reported |
| 2021-06-30 | $1.25B | $19.90B | $240.00M | $2.56B | $481.00M | 6.29% | 1.21% | 5.32× | Reported |
| 2021-03-31 | $1.17B | $18.86B | $241.00M | $2.29B | $500.00M | 6.20% | 1.28% | 4.58× | Reported |
| 2020-12-31 | $1.12B | $18.21B | $245.00M | $2.22B | $510.00M | 6.14% | 1.35% | 4.36× | Reported |
| 2020-09-30 | $1.10B | $17.12B | $244.00M | $1.48B | $528.00M | 6.40% | 1.43% | 2.81× | Reported |
| 2020-06-30 | $1.07B | $16.92B | $246.00M | $1.34B | $546.00M | 6.31% | 1.45% | 2.45× | Reported |
| 2020-03-31 | $1.09B | $17.41B | $250.00M | $1.61B | $567.00M | 6.24% | 1.44% | 2.83× | Reported |
| 2019-12-31 | $1.07B | $17.36B | $250.00M | $1.37B | $604.00M | 6.19% | 1.44% | 2.27× | Reported |
| 2019-09-30 | $1.06B | $17.29B | $261.00M | $1.76B | $639.00M | 6.14% | 1.51% | 2.75× | Reported |
| 2019-06-30 | $1.07B | $17.11B | $269.00M | $2.21B | $679.00M | 6.26% | 1.57% | 3.26× | Reported |
| 2019-03-31 | $1.06B | $17.04B | $267.00M | $2.10B | $705.00M | 6.25% | 1.57% | 2.98× | Reported |
| 2018-12-31 | $1.07B | $17.06B | $274.00M | $2.15B | $719.00M | 6.29% | 1.61% | 2.99× | Reported |
| 2018-09-30 | $1.01B | $15.98B | $322.00M | $1.50B | $706.00M | 6.29% | 2.01% | 2.12× | Reported |
| 2018-06-30 | $948.00M | $14.75B | $297.00M | $1.37B | $682.00M | 6.43% | 2.01% | 2.01× | Reported |
| 2018-03-31 | $858.00M | $13.50B | $282.00M | $634.00M | $683.00M | 6.35% | 2.09% | 0.93× | Reported |
| 2017-12-31 | $784.00M | $12.25B | $254.00M | $897.00M | $584.00M | 6.40% | 2.07% | 1.54× | Reported |
| 2017-09-30 | $774.00M | $12.09B | $174.00M | $1.48B | $521.00M | 6.40% | 1.44% | 2.84× | Reported |
| 2017-06-30 | $807.00M | $12.16B | $176.00M | $1.13B | $459.00M | 6.64% | 1.45% | 2.46× | Reported |
| 2017-03-31 | $827.00M | $12.32B | $176.00M | $1.87B | $373.00M | 6.71% | 1.43% | 5.01× | Reported |
| 2016-12-31 | $823.00M | $12.42B | $181.00M | $1.89B | $386.00M | 6.63% | 1.46% | 4.89× | Reported |
| 2016-09-30 | $828.00M | $12.48B | $196.00M | $1.43B | $388.00M | 6.63% | 1.57% | 3.69× | Reported |
| 2016-06-30 | $771.00M | $12.31B | $186.00M | $1.63B | $392.00M | 6.26% | 1.51% | 4.16× | Reported |
| 2016-03-31 | $743.00M | $12.23B | $193.00M | $1.25B | $400.00M | 6.07% | 1.58% | 3.13× | Reported |
| 2015-12-31 | $690.00M | $11.22B | $194.00M | $1.08B | $392.00M | 6.15% | 1.73% | 2.75× | Reported |
| 2015-09-30 | $632.00M | $10.28B | $166.00M | $1.07B | $371.00M | 6.15% | 1.61% | 2.89× | Reported |
| 2015-06-30 | $577.00M | $9.42B | $160.00M | $1.18B | $308.00M | 6.12% | 1.70% | 3.83× | Reported |
| 2015-03-31 | $535.00M | $8.46B | $138.00M | $1.49B | $235.00M | 6.32% | 1.63% | 6.34× | Reported |
| 2014-12-31 | $553.00M | $8.48B | $119.00M | $1.58B | $177.00M | 6.52% | 1.40% | 8.91× | Reported |
| 2014-09-30 | $550.00M | $8.45B | $113.00M | $1.61B | $135.00M | 6.51% | 1.34% | 11.90× | Reported |
| 2014-06-30 | $542.00M | $8.35B | $112.00M | $1.28B | $133.00M | 6.49% | 1.34% | 9.62× | Reported |
| 2014-03-31 | $526.00M | $8.24B | $109.00M | $1.24B | $135.00M | 6.38% | 1.32% | 9.19× | Reported |
| 2013-12-31 | $502.00M | $8.17B | $105.00M | $1.24B | $137.00M | 6.15% | 1.29% | 9.05× | Reported |
| 2013-09-30 | $494.00M | $8.05B | $100.00M | $1.25B | $138.00M | 6.13% | 1.24% | 9.09× | Reported |
| 2013-06-30 | $489.44M | $7.92B | $96.10M | $1.57B | $139.63M | 6.18% | 1.21% | 11.22× | Reported |
| 2013-03-31 | $483.31M | $7.85B | $93.68M | $1.61B | $139.90M | 6.16% | 1.19% | 11.52× | Reported |
| 2012-12-31 | $477.69M | $7.78B | $91.53M | $1.61B | $140.31M | 6.14% | 1.18% | 11.50× | Reported |
| 2012-09-30 | $471.75M | $7.71B | $89.05M | $1.56B | $134.66M | 6.12% | 1.16% | 11.57× | Reported |
| 2012-06-30 | $475.48M | $7.97B | $73.88M | $1.68B | $121.70M | 5.96% | 0.93% | 13.80× | Reported |
| 2012-03-31 | $474.27M | $7.94B | $73.46M | $1.67B | $109.06M | 5.97% | 0.92% | 15.36× | Reported |
| 2011-12-31 | $474.89M | $7.87B | $73.64M | $1.71B | $97.84M | 6.03% | 0.94% | 17.46× | Reported |
| 2011-09-30 | $476.50M | $7.83B | $73.36M | $1.76B | $84.02M | 6.09% | 0.94% | 20.99× | Reported |
| 2011-06-30 | (m) | $7.65B | $82.46M | $1.74B | $73.96M | (m) | 1.08% | 23.47× | Reported |
| 2011-03-31 | (m) | $7.47B | $80.63M | $1.69B | $64.84M | (m) | 1.08% | 26.02× | Reported |
| 2010-12-31 | (m) | $7.35B | $78.14M | $1.66B | $53.83M | (m) | 1.06% | 30.84× | Reported |
| 2010-09-30 | (m) | $7.37B | $79.37M | $1.68B | $51.26M | (m) | 1.08% | 32.71× | Reported |
| 2010-06-30 | (m) | $7.54B | $76.71M | $1.76B | $52.77M | (m) | 1.02% | 33.28× | Reported |
| 2010-03-31 | (m) | $7.48B | $82.57M | $1.75B | $50.97M | (m) | 1.10% | 34.29× | Reported |
| 2009-12-31 | (m) | $7.36B | $88.13M | $1.68B | $45.55M | (m) | 1.20% | 36.84× | Reported |
| 2009-09-30 | (m) | $7.16B | $86.57M | $1.65B | $40.39M | (m) | 1.21% | 40.86× | Reported |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-09-30 | (m) | $7.07B | $100.58M | $1.54B | $36.34M | (m) | 1.42% | 42.29× | Reported |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-09-30 | (m) | $6.28B | $107.71M | $1.18B | $46.42M | (m) | 1.71% | 25.52× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| BOSTON SCIENTIFIC CORP (BSX) | United States | $64.781B | 17.29 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |